EDIT vs JLL · rev $32.3M vs P/E 23, rev $23.43B
Editas Medicine Inc (EDIT) versus Jones Lang LaSalle Incorporated (JLL) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported JLL revenue for 2024-12-31 was $23.43B. Net income was $546.8M. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
EDIT currently screens at market cap $375.2M. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Not investment advice. Open the EDIT and JLL stock pages for the full models.
Not investment advice.